Ignite Creation Date:
2024-05-06 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04694157
Status:
UNKNOWN
Last Update Posted:
2022-01-06
First Post:
2020-04-17
Brief Title:
Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease Patients
Sponsor:
Beijing Hospital
Organization:
Beijing Hospital
Study Overview
Official Title:
Implication of Cardiac Shock Wave Therapy on Coronary Artery Disease Patients - An Observational Long-term Study
Status:
UNKNOWN
Status Verified Date:
2022-01
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
CAD is a challenging affliction which has a high annual morbidity rate in China and the world Severe CAD may lead to compromised cardiac function decreased exertional capacity and poor quality of life QOL The most common treatment for CAD is medication percutaneous coronary intervention PCI and coronary artery bypass graft CABG However some patients had long-term of history with complex severe artery lesions they are not candidate for redo interventional therapy Cardiac shock wave therapy CSWT is an exploring therapy used globally for CAD patients which is known for its safety non-invasiveness and effectivenessThe previous RCT from the investigators team has already finished and results are in submission processing
This is a prospective single arm observational study design CAD patients will be enrolled consecutively The entire treatment period will last 3 months with 9 sessions Outcomes are assessed as efficacy outcomes and safety outcomes Efficacy outcomes include symptom CCS score NYHA classification nitroglycerin dosage SAQ questionnaire exertional capacity 6MWT quality of life SF-36 questionnaire and imaging evaluation myocardial perfusion imaging and echocardiography Safety outcome include the change of serum TNT CKMB BNP and adverse event AE occurrence The participants will be followed up at 13th week 6th months and 12th months
This is a prospective single arm observational study design CAD patients will be enrolled consecutively The entire treatment period will last 3 months with 9 sessions Outcomes are assessed as efficacy outcomes and safety outcomes Efficacy outcomes include symptom CCS score NYHA classification nitroglycerin dosage SAQ questionnaire exertional capacity 6MWT quality of life SF-36 questionnaire and imaging evaluation myocardial perfusion imaging and echocardiography Safety outcome include the change of serum TNT CKMB BNP and adverse event AE occurrence The participants will be followed up at 13th week 6th months and 12th months
Detailed Description:
CAD is a challenging affliction which has a high annual morbidity rate in China and the world Severe CAD may lead to compromised cardiac function decreased exertional capacity and poor quality of life QOL The most common treatment for CAD is medication percutaneous coronary intervention PCI and coronary artery bypass graft CABG However some patients had long-term of history with complex severe artery lesions they are not candidate for redo interventional therapy Cardiac shock wave therapy CSWT is an exploring therapy used globally for CAD patients which is known for its safety non-invasiveness and effectiveness In the previous clinical studies CSWT can alleviated angina symptom improved myocardial ischemia and increased exertional capacity Many single arm studies proved its efficacy and safety Our RCT has already finished and results are in submission processing
This is a prospective single arm observational study design CAD patients will be enrolled consecutively The entire treatment period will last 3 months with 9 sessions CSWT will be administered in the first week follow by a 3-week non-treatment interval Outcomes are assessed as efficacy outcomes and safety outcomes Efficacy outcomes include symptom CCS score NYHA classification nitroglycerin dosage SAQ questionnaire exertional capacity 6MWT quality of life SF-36 questionnaire and imaging evaluation myocardial perfusion imaging and echocardiography Safety outcome include the change of serum TNT CKMB BNP and adverse event AE occurrence Symptom 6MWT and questionnaires will be evaluated at baseline and 13th week 6th months 12th months of CSWT Imaging outcomes will be evaluated at baseline and 13th week 12th months of CSWT The level of TNT CKMB and BNP will be tested before and 1st week after initiation of CSWT
This is a prospective single arm observational study design CAD patients will be enrolled consecutively The entire treatment period will last 3 months with 9 sessions CSWT will be administered in the first week follow by a 3-week non-treatment interval Outcomes are assessed as efficacy outcomes and safety outcomes Efficacy outcomes include symptom CCS score NYHA classification nitroglycerin dosage SAQ questionnaire exertional capacity 6MWT quality of life SF-36 questionnaire and imaging evaluation myocardial perfusion imaging and echocardiography Safety outcome include the change of serum TNT CKMB BNP and adverse event AE occurrence Symptom 6MWT and questionnaires will be evaluated at baseline and 13th week 6th months 12th months of CSWT Imaging outcomes will be evaluated at baseline and 13th week 12th months of CSWT The level of TNT CKMB and BNP will be tested before and 1st week after initiation of CSWT
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None